Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
German Clinical Trials Register |
Last refreshed on:
|
8 April 2024 |
Main ID: |
DRKS00012426 |
Date of registration:
|
09/05/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Clinical-practical validity of vegetative rhythms in peripheral physiological signals
|
Scientific title:
|
Clinical-practical validity of vegetative rhythms in peripheral physiological signals |
Date of first enrolment:
|
01/10/2020 |
Target sample size:
|
200 |
Recruitment status: |
Recruiting |
URL:
|
http://drks.de/search/en/trial/DRKS00012426 |
Study type:
|
interventional |
Study design:
|
Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: No treatment / Standard of care; Assignment: parallel; Study design purpose: basic science
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Germany
|
Switzerland
| | | | | | |
Contacts
|
Name:
|
Holger
Pelz |
Address:
|
Gothestr. 18
68161
Mannheim
Germany |
Telephone:
|
+491712856374 |
Email:
|
praxis@dr-holger-pelz.de |
Affiliation:
|
DGOM e.V. c/o Consalta |
|
Name:
|
Holger
Pelz |
Address:
|
Gothestr. 18
68161
Mannheim
Germany |
Telephone:
|
+491712856374 |
Email:
|
praxis@dr-holger-pelz.de |
Affiliation:
|
DGOM e.V. c/o Consalta |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Somatoform, psychosomatic and functional disorders and pain syndromes
Exclusion criteria: Absence of consent, minority, non-working persons, morphine medication, psychotropic medication, basic psychiatric disorders
Age minimum:
18 Years
Age maximum:
70 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
F45 R52.1
|
Chronic intractable pain
|
Somatoform disorders
|
R52.1
|
Intervention(s)
|
Group 1: osteopathic treatment: Vault Hold
osteopathic treatment: CV4
respectively at T0, T1, T2 at one week interval
Group 2: SHAM treatment
respectively at T0, T1, T2 at one week interval
|
Primary Outcome(s)
|
Pain at T0, T1, T2
|
Secondary Outcome(s)
|
SF12, MAIA 2, STAI 5, ICR-ICD10 Symptom Rating, change of physiological reactions T0, T1 (week 1), T2 (week 2)
|
Source(s) of Monetary Support
|
Head-Genuit-Stiftung, HGS
|
Ethics review
|
Status: Approved
Approval date: 03/04/2017
Contact:
ethikkommission@aekn.de
Ethikkommission bei der Ă„rztekammer Niedersachsen, Unterkommission zur Beurteilung medizinischer Forschung am Menschen
+49-511-3802208
ethikkommission@aekn.de
|
|